Love this-- Enzolytics’ ITV-1 therapy has completed Phase II clinical trials at a clinic in Bulgaria and is working on gaining FDA approval for the product in the U.S.
BioClonetics said that because of the similar structures of HIV and COVID-19 and the efficacy of its Clone 3 antibody in fighting HIV, the company has been asked by the National Science Foundation to submit a funding application for development of a COVID-19 antibody. The company currently has applications pending with the NSF and the National Institutes of Health.
“We look forward to discovering how ENZC's ITV-1 treatment can be used with our monoclonal antibody platform to synergistically improve our such antibodies for treating HIV,” Charles Cotropia said in a prepared statement.
Market Data 
Markets 
AI
